Article Details

Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination ...

Retrieved on: 2020-12-04 21:00:00

Tags for this article:

Click the tags to see associated articles and topics

Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination .... View article details on hiswai:

Excerpt

... across multiple lines of therapy, including as part of early-line CD20-targeted <b>monoclonal antibody</b> regimens, for the treatment of B-cell lymphoma.”.

Article found on: www.globenewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo